PhaseBio Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€697.71K - Cost of goods sold
€0.00 - Gross profit
€697.71K - SG&A expenses
€1.07M - R&D expenses
-€12.20M - EBITDA
€24.02M - D&A
€1.65M - EBIT
€25.04M - Interest expenses
€1.06M - EBT
€22.60M - Tax expenses
-€1.14M - Net income
€23.74M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€102.59M - Changes in working capital
€24.42M - Operating cash flow
-€50.68M - Capex
€2.05M - Other investing cash flow
€0.00 - Net investing cash flow
-€2.05M - Total cash dividends paid
€0.00 - Issuance of common stock
€1.64M - Debt repayment
€0.00 - Other financing cash flow
€4.41M - Net financing cash flow
€4.41M - Foreign exchange effects
€0.00 - Net change in cash
-€48.32M - Cash at end of period
€6.66M - Free cash flow
-€48.64M
Balance sheet
- Cash and cash equivalents
€6.66M - Cash and short-term investments
€6.66M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.21M - Total current assets
€9.86M - Property, plant & equipment
€8.99M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€49.47K - Total non-current assets
€9.04M - Total assets
€18.91M - Accounts payable
€5.39M - Short-term debt
€3.84M - Other current liabilities
€10.62M - Total current liabilities
€21.05M - Long-term debt
€741.21K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€90.90M - Total non-current liabilities
€97.99M - Total liabilities
€119.04M - Common stock
€42.65K - Retained earnings
-€357.90M - Other equity
€0.00 - Total equity
-€100.13M - Total liabilities and shareholders' equity
€18.91M
Company information
- Market capitalization
€0.00 - Employees
60 - Enterprise Value
-€33.96M
Company ratios
- Gross margin
-
100.0% Much better than peer group: -25,216.9% - EBITDA margin
-
3,443.2% Much worse than peer group: 5,109,377,224,725,093,000.0% - EBIT margin
-
3,588.2% Much worse than peer group: 5,092,902,505,661,701,000.0% - EBT margin
-
3,239.8% Much worse than peer group: 6,697,215,752,329,818,400.0% - Net margin
-
3,402.9% Much worse than peer group: 6,382,091,248,317,590,000.0% - ROE
-
-23.7% Much better than peer group: -89.5% - ROA
-
125.6% Much better than peer group: -400.0% - Asset turnover
-
3.7% Even with peer group: 5.7% - FCF margin
-
-7,557.7% Much worse than peer group: 1,888,582,408,519,292,000.0% - FCF yield
0.0% - Efficiency ratio
-3,343.2% - Net sales per employee
-
€11.63K - Net income per employee
-
€395.71K